Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Novartis-backed Inflazome, which advances University of Queensland and Trinity College Dublin research to develop treatments for inflammation, has been bought by Roche for $448m.

Inflazome, which advances University of Queensland and Trinity College Dublin research to develop treatments for inflammation, has been bought by Roche for $448m.

Compass Pathways has raised more than $127m in an upsized initial public offering that provided an exit to Otsuka Pharmaceuticals.

Legal & General is among the limited partners for Kindred Capital’s second fund, which also attracted University of Chicago and will invest in early-stage European startups.

University of Chicago is among the limited partners for Kindred Capital’s second fund, which will invest in early-stage European startups.

The Dutch multi-university venture fund had targeted $70m for its latest fund but ended up attracting $82.5m from investors including Protix and Corbion.

The Dutch multi-university venture fund had targeted $70m for its latest fund but ended up attracting $82.5m from investors including Protix and Corbion.

Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.

Novo Ventures and Sanofi Ventures co-led a series C round for the cancer therapy developer, which builds on work at Amsterdam UMC.